Kocher F, Hilbe W, Seeber A, Pircher A, Schmid T, Greil R, et al. Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry. Lung cancer (Amsterdam, Netherlands). 2015;87:193–200.
Article
Google Scholar
Yoshimoto A, Kasahara K, Kawashima A. Gastrointestinal metastases from primary lung cancer. Eur J Cancer (Oxford, England : 1990). 2006;42:3157–60.
Article
Google Scholar
Kim MS, Kook EH, Ahn SH, Jeon SY, Yoon JH, Han MS, et al. Gastrointestinal metastasis of lung cancer with special emphasis on a long-term survivor after operation. J Cancer Res Clin Oncol. 2009;135:297–301.
Article
PubMed
Google Scholar
Taira N, Kawabata T, Gabe A, Furugen T, Ichi T, Kushi K, et al. Analysis of gastrointestinal metastasis of primary lung cancer: clinical characteristics and prognosis. Oncol Lett. 2017;14:2399–404.
Article
PubMed
PubMed Central
Google Scholar
Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151:193–203.
Article
PubMed
Google Scholar
Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26:5043–51.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.
Article
CAS
PubMed
Google Scholar
Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K, et al. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2005;49:233–40.
Article
CAS
Google Scholar
Nokihara H, Lu S, Mok TSK, Nakagawa K, Yamamoto N, Shi YK, et al. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). Ann Oncol. 2017;28:2698–706.
Article
CAS
PubMed
PubMed Central
Google Scholar
Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009;27:3284–9.
Article
CAS
PubMed
Google Scholar
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–32.
Article
CAS
PubMed
Google Scholar
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16:141–51.
Article
CAS
PubMed
Google Scholar
Hanibuchi M, Kakiuchi S, Atagi S, Ogushi F, Shimizu E, Haku T, et al. A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease. Lung cancer (Amsterdam, Netherlands). 2018;125:93–9.
Article
Google Scholar
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.
Article
CAS
PubMed
Google Scholar
Scarpatetti M, Tsybrovskyy O, Popper HH. Cytokeratin typing as an aid in the differential diagnosis of primary versus metastatic lung carcinomas, and comparison with normal lung. Virchows Archiv. 2002;440:70–6.
Article
CAS
PubMed
Google Scholar
Werling RW, Yaziji H, Bacchi CE, Gown AM. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27:303–10.
Article
PubMed
Google Scholar
Bejarano PA, Baughman RP, Biddinger PW, Miller MA, Fenoglio-Preiser C, al-Kafaji B, et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol. 1996;9:445–52.
CAS
PubMed
Google Scholar
Moh M, Krings G, Ates D, Aysal A, Kim GE, Rabban JT. SATB2 expression distinguishes ovarian metastases of colorectal and appendiceal origin from primary ovarian tumors of mucinous or endometrioid type. Am J Surg Pathol. 2016;40:419–32.
Article
PubMed
Google Scholar
Hu Y, Feit N, Huang Y, Xu W, Zheng S, Li X. Gastrointestinal metastasis of primary lung cancer: an analysis of 366 cases. Oncol Lett. 2018;15:9766–76.
PubMed
PubMed Central
Google Scholar
Di JZ, Peng JY, Wang ZG. Prevalence, clinicopathological characteristics, treatment, and prognosis of intestinal metastasis of primary lung cancer: a comprehensive review. Surg Oncol. 2014;23:72–80.
Article
PubMed
Google Scholar
Lou Y, Dholaria B, Soyano A, Hodge D, Cochuyt J, Manochakian R, et al. Survival trends among non-small-cell lung cancer patients over a decade: impact of initial therapy at academic centers. Cancer Med. 2018;7:4932–42.
Article
PubMed
PubMed Central
Google Scholar
Lee PC, Lo C, Lin MT, Liang JT, Lin BR. Role of surgical intervention in managing gastrointestinal metastases from lung cancer. World J Gastroenterol. 2011;17:4314–20.
Article
PubMed
PubMed Central
Google Scholar